MGC Pharmaceuticals (ASX: MXC) (OTC: MGCLF) has announced confirmation that their strain contains an industry-high THC level of 35%.
First announced in on 1 February, the results have now been independently confirmed by the University of Ljubljana Biotechnical Facility and Pharma Lab in Slovenia.
While to a layman this might not seem significant, when compared to the top high-THC strains on the markets of Canada and USA, it exceeds competition.
Most high-THC strains are in the low-20% range, with Leafly reporting several OG strains as having the most THC: 28% – and CannabisIntel has not found a report of anything higher.
Along with the high-THC strain, MGC Pharma has also confirmed a high CBD strain containing over 20% CBD and <1% THC.
While MGC Pharma is not involved in the recreational use of cannabis, their high THC strain has significant impact on their operations and profitability.
MGC Pharma operates an eu-GMP certified facility in Slovenia, and currently has a range of phytomedicines and phytotherapeutics, all in oil form.
With their high-THC and CBD strains, MGC Pharma is able to deliver much larger yields in future cultivations, increasing output and lowering operational costs, which will flow on to a lower retail price for patients.